Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use

International Journal of Infectious Diseases

Volumn 14, Issue 5, 2010, Pages

  Valdés, Iris ^a   Hermida, Lisset ^a   Gil, Lázaro ^a   Lazo, Laura ^a   Castro, Jorge ^a   Martín, Jorge ^a   Bernardo, Lídice ^b   López, Carlos ^a   Niebla, Olivia ^a   Menéndez, Tamara ^a   Romero, Yaremis ^a   Sánchez, Jorge ^a   Guzmán, María G ^b   Guillén, Gerardo ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

Author keywords

Dengue virus; Green monkeys; Heterologous prime boost; Vaccines

Indexed keywords

RECOMBINANT PROTEIN; VIRUS ENVELOPE PROTEIN; DENGUE VACCINE; IMMUNOLOGICAL ADJUVANT; LPDA PROTEIN, NEISSERIA MENINGITIDIS; OUTER MEMBRANE PROTEIN; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; DENGUE VIRUS; DENGUE VIRUS 2; HAPLORHINI; HUMORAL IMMUNITY; NONHUMAN; ANIMAL; BLOOD; CERCOPITHECUS; DENGUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; METHODOLOGY; SERODIAGNOSIS; VERO CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; BACTERIAL OUTER MEMBRANE PROTEINS; CERCOPITHECUS AETHIOPS; DENGUE; DENGUE VACCINES; DENGUE VIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNIZATION; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; VERO CELLS;

EID: 77955867602     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2009.06.017     Document Type: Article

References (33)

1. st century. Trends Microbiol 2002, 10:100-103.
2. Halstead S.B. Dengue. Lancet 2007, 370:1644-1652.
3. Guirakhoo F., Kitchener S., Morrison D., Forrat R., McCarthy K., Nichols R., et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006, 2:60-67.
4. Guy B., Nougarede N., Begue S., Sanchez V., Souag N., Carre M., et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 2008, 26:5712-5721.
5. Simasathien S., Thomas S.J., Watanaveeradej V., Nisalak A., Barberousse C., Innis B.L., et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg 2008, 78:426-433.
6. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 2002, 66:264-272.
7. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 2004, 23:99-109.
8. Srivastava A., Putnak J.R., Warren R.L., Hoke C.H. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine 1995, 13:1251-1258.
9. Simmons M., Nelson W.M., Wu S.J., Hayes C.G. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am J Trop Med Hyg 1998, 58:655-662.
10. Velzing J., Groen J., Drouet M.T., van Amerongen G., Copra C., Osterhaus A.D., et al. Induction of protective immunity against dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines. Vaccine 1999, 17:1312-1320.
11. Simmons M., Murphy G.S., Hayes C.G. Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med Hyg 2001, 65:159-161.
12. Guzmán M.G., Rodríguez R., Rodríguez R., Hermida H., álvarez M., Lazo L., et al. Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. Am J Trop Med Hyg 2003, 69:129-134.
13. Putnak R.J., Coller B.A., Voss G., Vaughn D.W., Clements D., Peters I., et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 2005, 23:4442-4452.
14. Hermida L., Bernardo L., Martín J., álvarez M., Prado I., López C., et al. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 2006, 24:3165-3171.
15. Simmons M., Porter K.R., Hayes C.G., Vaughn D.W., Putnak R. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J Virol 2006, 80:9577-9585.
16. Bernardo L., Izquierdo A., álvarez M., Rosario D., Prado I., López C., et al. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res 2008, 80:194-199.
17. Lazo L., Zulueta A., Hermida L., Blanco A., Sánchez J., Valdés I., et al. The dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice. Biotechnol Appl Biochem 2009, 52:265-271.
18. Valdés I., Hermida L., Martín J., Menéndez T., Gil L., Lazo L., et al. Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis. Vaccine 2009, 27:995-1001.
19. González G., Crombet T., Catalá M., Mirabal V., Hernández J.C., González Y., et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol 1998, 9:431-435.
20. Pérez A., Dickinson F., Cinza Z., Ruiz A., Serrano T., Sosa J., et al. Safety and preliminary immunogenicity of the recombinant outer membrane protein P64k of Neisseria meningitidis in human volunteers. Biotechnol Appl Biochem 2001, 34:121-125.
21. Zulueta A., Hermida L., Lazo L., Valdés I., Rodríguez R., López C., et al. The fusion site of envelope fragments from each serotype of dengue virus in the P64k protein, influence some parameters of the resulting chimeric construct. Biochem Biophys Res Commun 2003, 308:619-626.
22. Hermida L., Rodríguez R., Lazo L., Bernardo L., Silva R., Zulueta A., et al. A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice. Biotechnol Appl Biochem 2004, 39:107-114.
23. Hermida L., Rodríguez R., Lazo L., Silva R., Zulueta A., Chinea G., et al. A dengue-2 envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J Virol Methods 2004, 115:41-49.
24. Churdboonchart V., Bhamarapravati N., Peampramprecha S. Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. Am J Trop Med Hyg 1991, 44:481-493.
25. Morens D.M., Halstead S.B., Repik P.M. Simplified plaque reduction assay for dengue viruses by semimicro methods in BHK 21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol 1985, 22:250-254.
26. Van der Most R.G., Murali-Krishna K., Ahmed R. Prolonged presence of effector-memory CD8 T cells in the central nervous system after dengue virus encephalitis. Intern Immunol 2003, 15:119-125.
27. Mongkolsapaya J., Duangchinda T., Dejnirattisai W., Vasanawathana S., Avirutnan P., Jairungsri A., et al. T cell response in dengue hemorrhagic fever: are cross-reactive T cells suboptimal?. J Immunol 2006, 176:3821-3829.
28. Dale C.J., Thomson S., De Rose R., Ranasinghe C., Medveczky C.J., Pamungkas J., et al. Prime-boost strategies in DNA vaccines. Methods Mol Med 2006, 127:171-197.
29. Chen L., Ewing D., Subramanian H., Block K., Rayner J., Alterson K.D. A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques. J Virol 2007, 81:11634-11639.
30. Brandler S., Lucas-Hourani M., Moris A., Frenkiel M.P., Combredet C., Février M., et al. Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Negl Trop Dis 2007, 1:e96.
31. Khanam S., Rajendra P., Khanna N., Swaminathan S. An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes. BMC Biotechnol 2007, 7:10.
32. Bernardo L., Hermida L., Martin J., álvarez M., Prado I., López C., et al. Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins. Arch Virol 2008, 153:849-854.
33. Putnak R., Fuller J., VanderZanden L., Innis B.L., Vaughn D.W. Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-membrane and envelope genes. Am J Trop Med Hyg 2003, 68:469-476.